Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of first-in-class oral triplet therapy DTRM-555 in relapsed/refractory lymphoma patients through fixed-dose combination and synthetic lethality
    Meeting Abstract

    Huntington, S. F.; Schuster, S. J.; He, W.; Shen, T.; Walker, H.; Leary, L.; Boyhen, K.; Gill, J.; Chatburn, E. T.; Kennard, K.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Treatment patterns, adverse events, and economic burden in a privately insured population of newly diagnosed patients with chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Kabadi, S.; Goyal, R. K.; Nagar, S. P.; Kaye, J. A.; Davis, K. L.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • FLT3-ITD mutations are prevalent and significantly impact outcome after intensive therapy in elderly adults with acute myeloid leukemia (AML): Analysis of the North American Intergroup E2906 phase III trial in patients age ≥ 60 years
    Meeting Abstract

    Foran, J. M.; Sun, Z.; Paietta, E.; Racevskis, J.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Godwin, J.; Zhang, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Patients' perspectives on the definition of cure in chronic myeloid Leukemia: A US based survey
    Meeting Abstract

    George, G.; Atallah, E. L.; Mauro, M. J.; Goldberg, S. L.; Baim, A.; Guhl, J.; Hinman, A.; Cortes, J. E.; Deininger, M. W.; Druker, B. J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Survival advantage to allogeneic transplant in patients with myelofibrosis with intermediate-1 or higher DIPSS score
    Meeting Abstract

    Gowin, K. L.; Ballen, K. K.; Ahn, K. W.; Hu, Z. H.; Liu, Y.; Masarova, L.; Verstovsek, S.; Coakley, M.; Jain, T.; Kuykendall, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of MRD negativity in adults ages 18-60 with Philadelphia chromosome-negative acute lymphoblastic leukemia and lymphoblastic lymphoma
    Meeting Abstract

    Geyer, M. B.; Ritchie, E. K.; Rao, A. V.; Cazacu, M. I.; Vemuri, S.; Tallman, M. S.; Douer, D.; Park, J. H.
    Blood (2018)

    Fulltext@MSK | Save
  • Outcomes of ibrutinib therapy given after prior venetoclax therapy in ibrutinib-naïve patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Brown, J. R.; Davids, M. S.; Chang, J. L.; Ma, S.; Biondo, J.; Mobasher, M.; Mun, Y.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas
    Meeting Abstract

    Chong, E. A.; Svoboda, J.; Nasta, S. D.; Landsburg, D. J.; Winchell, N.; Napier, E.; Mato, A. R.; Melenhorst, J. J.; Ruella, M.; Lacey, S. F.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetic, and pharmacodynamic results from a phase 1b/2 dose-escalation and cohort-expansion study of the noncovalent, reversible Bruton's tyrosine kinase inhibitor (BTKi), vecabrutinib, in B-lymphoid malignancies
    Meeting Abstract

    Allan, J. N.; Wierda, W. G.; Patel, K.; O'Brien, S. M.; Mato, A. R.; Davids, M. S.; Furman, R. R.; Pagel, J. M.; Fox, J. A.; Ward, R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase 1b dose escalation study of BI 836858 and azacitidine in previously untreated AML: Results from Beat AML S2
    Meeting Abstract

    Blum, W.; Ruppert, A. S.; Mims, A. S.; Stein, E. M.; Duong, V. H.; Odenike, O.; Patel, P. A.; Kovacsovics, T.; Heerema, N. A.; Vergilio, J. A.; more...
    Blood (2018)

    Fulltext@MSK | Save